The m(6)A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients

m(6)A相关mRNA特征可预测胰腺癌患者的预后

阅读:1

Abstract

N(6)-methyladenosine (m(6)A) has an important epitranscriptomic modification that controls cancer self-renewal and cell fate. The addition of m(6)A to mRNA is a reversible modification. The deposition of m(6)A is encoded by a methyltransferase complex involving three homologous factors, jargonized as "writers," "erasers," and "readers." However, their roles in pancreatic adenocarcinoma (PAAD) are underexploited. With the use of The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases, we provided an mRNA signature that may improve the prognostic prediction of PAAD patients based on the genetic status of m(6)A regulators. PAAD patients with genetic alteration of m(6)A regulators had worse disease-free and overall survival. After comparing PAAD groups with/without genetic alteration of m(6)A regulators, we identified 196 differentially expressed genes (DEGs). Then, we generated a 16-mRNA signature score system through least absolute shrinkage and selection operator (LASSO) Cox regression analysis. Multivariate cox regression analysis demonstrated that a high-risk score significantly correlates with poor prognosis. Moreover, time-dependent receiver operating characteristic (ROC) curves revealed it was effective in predicting the overall survival in both training and validation sets. PAH, ZPLD1, PPFIA3, and TNNT1 from our signature also exhibited an independent prognostic value. Collectively, these findings can improve the understanding of m(6)A modifications in PAAD and potentially guide therapies in PAAD patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。